Skip to content
Datasets/BEATAML1.0-CRENOLANIB

Clinical Resistance to Crenolanib in Acute Myeloid Leukemia Due to Diverse Molecular Mechanisms

Underused opportunityControlledMachine-extracted
BEATAML1.0Available from GDC

Can it answer your research question?

1 of 6 supported
  • Overall survival

    Limited

    Vital status is informative for 100% of cases, but too few events or no time to event.API

  • Progression or recurrence

    Supported

    progression_or_recurrence is informative for 100% of cases.API

  • Treatment response

    Not supported

    treatment_outcome is populated for no case in the harmonized records.API

  • Which drug was given

    Not supported

    therapeutic_agents is recorded for no case in the harmonized records.API

  • Stage-adjusted modelling

    Not supported

    ajcc_pathologic_stage is informative for no case in the harmonized records.API

  • Analysis by race or ethnicity

    Not supported

    Race is informative for no case in the harmonized records.API

Judged from the repository’s own field completeness (thresholds). “Not measured” means we have not probed that field for this record, not that the data lack it.

At a glance

Every percentage is the repository’s own record of what is filled in
CasesAPI
56
Measurement types
1
547 files, 3.3 TB
Follow-upAPI
None recorded
no survival endpoint
Treatment responseAPI
Not recorded

SubjectCALC

Myeloid

As filed by the repository

Myeloid LeukemiasHematopoietic and reticuloendothelial systems

Who is in the cohortAPI

A usable value“Not reported” or “unknown”No value recorded
  • Sex30 female · 26 male
  • Race56 not reported
  • Ethnicity56 not reported
  • Vital status56 dead

What was measured, and on how many

1 measurement type, 1 covering the whole cohort.

  • Whole exome sequencing56 of 56 · 100%
Platform, files and data levels
AssayPlatformFilesLevels
Whole exome sequencingAPIillumina547-
How complete all 29 clinical fields are - 6 informative for at least 80% of cases

A field counts as informative only when it holds a real value. “Not reported” blocks an analysis just as a missing field does. Fields marked 1:n can hold several records per case, so they show the share of cases with any record.

Informative - a usable valuePresent but uninformative - “not reported” or “unknown”Absent - no value recorded

Outcome

  • Vital statusAPI100%
  • Progression or recurrenceAPI100%
  • Cause of deathAPI0%
  • Last known disease statusAPI0%

Follow-up

  • Disease response at follow-upAPI0%
  • Progression at follow-upAPI0%
  • ECOG performance statusAPI0%

Treatment

  • Prior treatmentAPI0%
  • Treatment typeAPI0%
  • Treatment givenAPI0%
  • Therapeutic agentsAPI0%
  • Treatment outcomeAPI0%
  • Regimen or line of therapyAPI0%

Staging

  • AJCC pathologic stageAPI0%
  • AJCC clinical stageAPI0%

Diagnosis

  • Primary diagnosisAPI100%
  • Tissue or organ of originAPI100%
  • Prior malignancyAPI0%
  • Synchronous malignancyAPI0%

Pathology

  • Morphology (ICD-O)API100%
  • Tumor gradeAPI0%
  • Classification of tumorAPI0%

Demographics

  • Sex at birthAPI100%
  • RaceAPI0%
  • EthnicityAPI0%
  • Population groupAPI0%
  • Country of residenceAPI0%

Exposure

  • Tobacco smoking statusAPI0%
  • Alcohol historyAPI0%

Access

ControlledFormal data access request and institutional approval.

Data Access Request through dbGaP using an eRA Commons account; institutional signing official approval required

Controlled components
547 controlled-access files
Typical turnaround
days to a few weeks after signing official approval
License
NIH Genomic Data Sharing Policy terms
Citation requirement
Cite the dataset accession and the program's publication guidelines; see the GDC publication policy.

What it is good for

Written and checked by a reviewer, not generated from metadata.

No reviewed research questions yet. The measurements and field completeness above are machine-extracted and still useful for judging fit.

What it cannot tell you

Written by a reviewer against the source, not inferred from what is missing.

No reviewed limitations yet. Check the field completeness chart above before committing to an analysis. Low coverage on an endpoint you need is the most common blocker.

Who has used it

Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.

Analyzed the dataCALC2
0
accession in the methods section
Declared using it
2
named in a data availability statement
Cited the paper
-
attention to the publication, not reuse of the data
Against expectation
Well below
about 3 articles expected; index -2.09

What articles did with it

Only the last row counts as reuse. Where the accession appears in an article tells us what the authors did with the data.

  • Mentioned the dataset0
  • Accession found in text1
  • Declared using it2
  • Analyzed the data0

Against comparable datasets

No article has analyzed these data. About 3 would be expected. The expectation comes from a model of size, age, breadth and access tier.

  • Analyzed it0
  • Expected~3
Why this is an underused opportunity
  • 0 article(s) reference this dataset's accession in a methods section, against 3.3 predicted for datasets of comparable size, age, modality breadth and access tier (reuse gap index -2.09 on a log2 scale, 10th percentile of the assessed corpus).

Compared against 132 datasets in this corpus with a citable accession and sufficient metadata. See Methods for the model.

Possible original publication, unverified

No repository or reviewer names this dataset’s marker paper, so this is the pipeline’s own guess: the earliest heavily cited article that analysed the accession and names it in full text. Nothing is counted from it - not the citation figure above, not the funding attribution - and it is queued for review rather than presented as fact.

Articles that analyzed the data

None found. We searched Europe PMC for this dataset's accessions in article methods, results, tables, figures and data availability statements on 20 Sept 2026. That means our search found nothing, not that nobody has used these data.

1 article with weaker evidence

These name the dataset, but we could not confirm the data were analyzed. Shown for completeness and not counted as reuse.

Community examples

Share your example

Analyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.

Nobody has shared an analysis of this dataset yet. The examples on other datasets cover the common patterns and can be adapted - and if you adapt one, it belongs here.

Start here

Starter code generated from this record’s own identifiers, then the access steps.

Get the data in code

GDC: list open files and download thempython

Open-access files need no account. Controlled files need an approved dbGaP request and a token passed to gdc-client.

import json, requests

PROJECT = "BEATAML1.0-CRENOLANIB"
filters = {"op": "and", "content": [
    {"op": "in", "content": {"field": "cases.project.project_id", "value": [PROJECT]}},
    {"op": "in", "content": {"field": "access", "value": ["open"]}},
]}
params = {"filters": json.dumps(filters),
          "fields": "file_id,file_name,data_category,data_type,file_size",
          "size": "10000", "format": "JSON"}
files = requests.get("https://api.gdc.cancer.gov/files", params=params, timeout=60).json()["data"]["hits"]
print(len(files), "open files")

# Write a manifest and fetch with the GDC client (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool)
with open("manifest.txt", "w") as fh:
    fh.write("id\n" + "\n".join(f["file_id"] for f in files))
# $ gdc-client download -m manifest.txt
GDC: clinical table for every casepython
import json, requests

filters = {"op": "in", "content": {"field": "project.project_id", "value": ["BEATAML1.0-CRENOLANIB"]}}
params = {"filters": json.dumps(filters), "size": "5000", "format": "TSV",
          "fields": ",".join([
              "submitter_id", "demographic.vital_status", "demographic.days_to_death",
              "diagnoses.days_to_last_follow_up", "diagnoses.ajcc_pathologic_stage",
              "diagnoses.treatments.treatment_type", "diagnoses.treatments.treatment_outcome"])}
tsv = requests.get("https://api.gdc.cancer.gov/cases", params=params, timeout=60).text
open("BEATAML1.0-CRENOLANIB_clinical.tsv", "w").write(tsv)
This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/gdc-beataml1.0-crenolanib.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
    print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'

Access steps

  1. 1
    Open the project in the GDC Data PortalFor people5 minutes

    Check the portal's current case and file counts before requesting anything; the cohort can change after this record was built.

    https://portal.gdc.cancer.gov/projects/BEATAML1.0-CRENOLANIB

    Generated from repository policy. Check the linked policy before downloading.

  2. 2
    Request controlled access through dbGaPFor peopledays to a few weeks after signing official approval

    547 controlled-access files require an approved data access request. The request starts at dbGaP, not in the portal. The relevant study is phs001628.

    Requires: eRA Commons account, institutional signing official approval, dbGaP data access request for phs001628

    https://gdc.cancer.gov/access-data/obtaining-access-controlled-data

    Generated from repository policy. Check the linked policy before downloading.

  3. 3
    Download controlled files with your tokenFor people

    An approved request yields a token. The same manifest fetches nothing controlled without it.

    Requires: approved dbGaP request, GDC authentication token

    gdc-client download -m gdc_manifest.txt -t gdc-user-token.txt
    https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001628

    Generated from repository policy. Check the linked policy before downloading.

  4. 4
    Query the project from code, with no credentialsFor agents

    The file index is public even where files are not, so an agent can size the cohort before anyone requests access.

    curl -s 'https://api.gdc.cancer.gov/files' --get \
      --data-urlencode 'filters={"op":"in","content":{"field":"cases.project.project_id","value":["BEATAML1.0-CRENOLANIB"]}}' \
      --data-urlencode 'fields=file_id,file_name,data_type' \
      --data-urlencode 'size=10000' --data-urlencode 'format=TSV'
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

  5. 5
    Pass the token when the agent needs controlled filesFor agents

    Without a token, an API query may return only the open subset. Compare returned counts with the record before treating them as the whole cohort.

    Requires: GDC authentication token

    curl -H "X-Auth-Token: $GDC_TOKEN" https://api.gdc.cancer.gov/data/<file_id>
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

Provenance

All of it, and more, is in this record’s JSON.

Identifiers

Versions and verification

Released
1 Jan 2018
Metadata retrieved
18 Sept 2026
Review status
Machine-extracted
Data generation funding
Funded data generation

Funding

Awards resolved through NIH RePORTER. Awards that paid to generate these data are listed apart from awards that paid to reuse them. Both are returns on NCI investment, but different ones.

Funded reuse of these data

  • R00CA237630Characterizing the pathogenesis and targeted therapeutics of Wilms' Tumor 1 (WT1) mutations in AMLHaijiao ZhangFY2021-2023API
  • K99CA237630Characterizing the pathogenesis and targeted therapeutics of Wilms' Tumor 1 (WT1) mutations in AMLHaijiao ZhangFY2019-2020API

Funded infrastructure or harmonization

  • U54CA224019Architecture and Trajectory of Acquired Resistance to Therapy in AMLBRIAN J DRUKER, Shannon K. McWeeneyFY2017-2026API
  • U01CA217862Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic MalignanciesBRIAN J DRUKER, Jeffrey Wallace TynerFY2017-2021API
  • U01CA214116Proteogenomic Translational Research Center for Clinical ProteomicBRIAN J DRUKER, Karin D RodlandFY2017-2021API

For softwarerecord JSON